ArticleFrontiers in psychiatry2026
Case Report: A rare phenomenon of venlafaxine induced vocal tics.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Venlafaxine is a serotonin norepinephrine reuptake inhibitor, an effective medication widely used in many psychiatric conditions, including major depressive disorder and generalized anxiety disorder. It is a relatively safe and tolerated medication. Despite that, it has some side effects affecting many systems, including nausea, insomnia, and tremors. Also, it has some neuropsychiatric side effects, such as akathisia. Venlafaxine induced akathisia has been reported in some studies. Several antidepressants have been associated with some neuropsychiatric manifestations, including tics, usually motor, but not vocal. In our study, we reported a rare side effect of venlafaxine, which is venlafaxine-induced vocal tics. Case presentation: A 57-year-old women was diagnosed with anxiety and started on venlafaxine with a good response for three months. Then she stopped it. Her anxiety symptoms started to appear again. Then she re-initiated venlafaxine again. A few days afterwards she started to develop vocal tics that are frequent and distressing to the patient. The Yale Global Tic Severity Scale (YGTSS) score at presentation was 22 (Total Tic Score), indicating moderate severity, with an impairment score of 20. Causality assessment using the Naranjo Adverse Drug Reaction Probability Scale yielded a score of 7, indicating a probable relationship between and the vocal tics. Discussion: To our knowledge, this appears to be the first reported case of venlafaxine induced vocal tics. On the other hand, there were previous reports on Sertraline and Mirtazapine. Previous studies reported associations of tics with SSRIs and atypical antidepressants but not SNRIs. Also, our study is the first study that reported "vocal" tics in association with antidepressant. The proposed mechanism involves a complex interaction between serotonergic augmentation and dopaminergic dysregulation in fronto-striatal circuits, in which increased serotonin levels may indirectly modulate dopamine concentrations to express tics in susceptible individuals. Conclusion: Our findings suggest that venlafaxine may induce vocal tics. Physicians should consider venlafaxine as a potential cause when patients develop vocal tics while on treatment. Early detection and discontinuation of the medication can prevent complications and lead to symptom resolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.